Relative resistance to mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors

Ochsner Journal

Volumn 13, Issue 1, 2013, Pages 56-60

  Lightell, Daniel J ^a   Woods, T Cooper ^a,b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Cyclin dependent kinase inhibitor p27; TOR serine threonine kinases; Vascular smooth muscle

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; DRUG RESISTANCE; DRUG RESPONSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; SMOOTH MUSCLE FIBER;

EID: 84875202625     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012 Jan 3;125(1):e2-e220. Epub 2011 Dec 15. Erratum in: Circulation. 2012 Jun 5;125(22):e1002.
2. Nilsson-Berglund LM, Zetterqvist AV, Nilsson-Ohman J, et al. Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetesinduced hyperglycemia. Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2):218-224. Epub 2009 Dec 3.
3. Wendt T, Bucciarelli L, Qu W, et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep. 2002 May;4(3):228-237.
4. Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6): 2482-2487.
5. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR. Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology. 2007 May;148(5):2435-2443. Epub 2007 Jan 25.
6. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest. 1997 Nov 1;100(9): 2158-2169.
7. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000 Nov;49(11):1939-1945.
8. Nakanishi H, Brewer KA, Exton JH. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1993 Jan 5;268(1):13-16.
9. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1142-1147. Epub 2005 Mar 31.
10. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009 Apr 7;119(13):1728-1735. Epub 2009 Mar 23.
11. Kim TN, Kim S, Yang SJ, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010 Mar;3(2):142-148. Epub 2010 Jan 8.
12. Collet CA, Costa JR, Abizaid A, et al. Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents. JACC Cardiovasc Interv. 2011 Oct;4(10):1067-1074.
13. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation. 1997 Mar 18;95(6):1366-1369.
14. Lightell DJ Jr, Moss SC, Woods TC. Loss of canonical insulin signaling accelerates vascular smooth muscle cell proliferation and migration through changes in p27Kip1 regulation. Endocrinology. 2011 Feb;152(2):651-658. Epub 2010 Dec 29.
15. Ahanchi SS, Varu VN, Tsihlis ND, et al. Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am J Physiol Heart Circ Physiol. 2008 Dec; 295(6):H2388-H2398. Epub 2008 Oct 17.
16. Wang CC, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes. 2003 Oct;52(10):2562-2569.
17. Nakashima Y, Chen YX, Kinukawa N, Sueishi K. Distributions of diffuse intimal thickening in human arteries: preferential expression in atherosclerosis-prone arteries from an early age. Virchows Arch. 2002 Sep;441(3):279-288. Epub 2002 Mar 14.
18. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007 May;27(5):1159-1165. Epub 2007 Feb 15.
19. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res. 2008 Jul 1;79(1):14-23. Epub 2008 Apr 22.
20. Tanner FC, Yang ZY, Duckers E, et al. Expression of cyclindependent kinase inhibitors in vascular disease. Circ Res. 1998 Feb 23;82(3):396-403.
21. Sun J, Marx SO, Chen HJ, et al. Role for p27(kip1) in vascular smooth muscle cell migration. Circulation. 2001 Jun 19;103(24): 2967-2972.
22. Chen D, Krasinski K, Sylvester A, et al. Downregulation of cyclindependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest. 1997 May 15;99(10):2334-2341.
23. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999 Apr 27; 99(16):2164-2170.
24. Luo Y, Marx SO, Kiyokawa H, et al. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol. 1996 Dec;16(12): 6744-6751.
25. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995 Mar;76(3):412-417.
26. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996 Nov 15;98(10): 2277-2283.
27. Weisz G, Leon MB, Holmes DR Jr, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006 Apr 4;47(7):1350-1355. Epub 2006 Mar 20.
28. Moses JW, Leon MB, Popma JJ, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2; 349(14):1315-1323.
29. Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011 Aug 23;124(8):893-900. Epub 2011 Aug 8.
30. Moss SC, Lightell D Jr, Deichmann RE Jr, Woods TC. Sera from patients with diabetes do not alter the effect of mammalian target of rapamycin inhibition on smooth muscle cell proliferation. J Cardiovasc Pharmacol. 2009 Jan;53(1):86-89.
31. Moss SC, Lightell DJ Jr, Marx SO, Marks AR, Woods TC. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem. 2010 Apr 16;285(16):11991-11997. Epub 2010 Jan 22.
32. Wu YJ, Sala-Newby GB, Shu KT, et al. S-phase kinase-associated protein-2 (Skp2) promotes vascular smooth muscle cell proliferation and neointima formation in vivo. J Vasc Surg. 2009 Nov;50(5):1135-1142.
33. Jonas M, Edelman ER, Groothuis A, et al. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res. 2005 Sep 30;97(7):725-733. Epub 2005 Aug 25.